Breaking Finance News

A statement released earlier today by RBC Capital Markets about Prothena Corp (NDAQ:PRTA) raises the target price to $87.00

Only yesterday Prothena Corp (NDAQ:PRTA) traded 4.67% higher at $64.74. Prothena Corp’s 50-day average is $59.39 and its two hundred day average is $56.18. With the last stock price close up 16.88% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same time. 136,187 shares of PRTA traded, down from an avg. volume of 291,070

In a report released on 9/15/2017 RBC Capital Markets upped the price target of Prothena Corp (NDAQ:PRTA) to $87.00 reporting a potential upside of 0.34%.

On 8/17/2017, Evercore ISI reported on Prothena Corp (NDAQ:PRTA) raised the target price from $0.00 to $83.00. At the time, this indicated a possible upside of 0.48%.

Performance Chart

Prothena Corp (NDAQ:PRTA)

With a total market value of $0, Prothena Corp has with a 52 week low of $40.58 and a 52 week high of $69.53 .

Also covering Prothena Corp's target, a total of 7 equity analysts have released a research note on Prothena Corp. The 12-month price target is $73.86 with four firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the company a sell.

General Company Details For Prothena Corp (NDAQ:PRTA)

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.